MeSH term
Frequency | Condition_Probility | Animals | 25 | 0.0 |
Humans | 46 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Mice | 10 | 0.0 |
Microsatellite Repeats | 2 | 0.0 |
Molecular Sequence Data | 17 | 0.0 |
Rats | 12 | 0.0 |
Research Support, Non-U.S. Gov't | 34 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Amino Acid Sequence | 8 | 0.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Conserved Sequence | 3 | 0.0 |
Neuropeptides/*genetics | 3 | 6.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Organ Specificity | 2 | 0.0 |
Aged | 4 | 0.0 |
Alleles | 4 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Female | 18 | 0.0 |
Human Growth Hormone/*genetics | 5 | 35.0 |
Male | 18 | 0.0 |
Middle Aged | 5 | 0.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 20 | 0.0 |
Adolescent | 4 | 0.0 |
Child | 3 | 0.0 |
Point Mutation | 3 | 0.0 |
Adult | 6 | 0.0 |
Genetic Markers | 5 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
*Alleles | 2 | 0.0 |
Chromosomes, Human, Pair 17/*genetics | 2 | 1.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Exons | 4 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Base Sequence | 14 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Genotype | 2 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
Growth Hormone/*genetics | 7 | 19.0 |
Linkage (Genetics) | 2 | 0.0 |
Pedigree | 4 | 0.0 |
Child, Preschool | 4 | 0.0 |
*Mutation | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
*Linkage (Genetics) | 5 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Sodium Channels/*genetics | 4 | 4.0 |
Cell Division/drug effects | 3 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Somatotropin-Releasing Hormone/pharmacology | 2 | 4.0 |
Comparative Study | 5 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
Lod Score | 3 | 0.0 |
Species Specificity | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Cell Line | 7 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
*Chromosomes, Human, Pair 17 | 5 | 0.0 |
Hamsters | 2 | 0.0 |
Binding Sites | 2 | 0.0 |
Kinetics | 3 | 0.0 |
Pituitary Neoplasms/*secretion | 2 | 4.0 |
*Genes, Dominant | 2 | 0.0 |
Introns | 2 | 0.0 |
Mutation | 4 | 0.0 |
DNA/genetics | 5 | 0.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Triiodothyronine/pharmacology | 2 | 4.0 |
Chromosomes, Human, Pair 17 | 2 | 0.0 |
Triiodothyronine/*pharmacology | 2 | 4.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Hyperkalemia/*genetics | 2 | 50.0 |
Paralyses, Familial Periodic/*genetics | 2 | 25.0 |
Molecular Weight | 2 | 0.0 |
Pituitary Neoplasms | 2 | 11.0 |
*Chromosome Deletion | 2 | 0.0 |
Haplotypes | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Growth Disorders/*genetics | 3 | 5.0 |
Growth Hormone/deficiency/*genetics | 2 | 100.0 |
Amino Acids/analysis | 2 | 0.0 |
